Trulicity vs. Rybelsus
Trulicity and Rybelsus, both GLP-1 agonists, differ in formulation and scope. Trulicity is an injectable drug for type 2 diabetes management, while Rybelsus is an oral alternative for the same condition. Trulicity provides superior HbA1c reductions and modest weight loss compared to Rybelsus. Both are occasionally used off-label for weight management. Side effects like nausea are common, with Rybelsus also causing gastrointestinal discomfort. Trulicity costs $875/month, similar to Rybelsus’s $875/month. Neither drug faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, fatigue, and decreased appetite.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions